Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 8, 1997, Pages 665-680

  Rohatagi, Shashank ^a,c   Barrett, Jeffrey S ^a   Dewitt, Kimberly E ^a   Lessard, Denis ^b   Morales, Richard J ^a  

^a Somerset Pharmaceuticals   (United States)

^b MDS Inc   (Canada)

^c SANOFI   (France)

Author keywords

Pharmacokinetics; Pulsatile delivery; Selegiline

Indexed keywords

DRUG METABOLITE; SELEGILINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS;

ADMINISTRATION, ORAL; ADULT; AMPHETAMINE; AMPHETAMINES; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINAL ABSORPTION; MALE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITORS; PILOT PROJECTS; REFERENCE VALUES; SELEGILINE; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 0030667350     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199711)18:8<665::AID-BDD47>3.0.CO;2-A     Document Type: Article

References (11)

1. The Parkinson's Study Group. Effect of deprynl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321, 1364 (1989).
2. V. V. Myllylä, K. A. Sotaniemi, J. A. Vuorinen and E. H. Heinonen, Selegiline as initial treatment in de novo Parkinsonian patients. Neurology. 42, 339 (1992).
3. R) facilitates the activity of the nigostriatal dopaminergic neuron. J. Neural. Transm., 25 (suppl.), 45 (1987).
4. J. D. Elsworth, V. Glover, G. P. Reynolds, M. Sandler, A. J. Lees, P. Phuapradit, K. M. Shaw, G. M. Stern and P. Kumar, Deprynl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology. 57, 33 (1978).
5. R (selegiline hydrochloride). Am. J. Ther., 3, 298 (1996).
6. P. Chrisp, G. J. Mammen and E. M. Sorkin, Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1, 228 (1991).
7. T. Yoshida, Y. Yamada, T. Yamamoto and I. Kuroiwa, Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitor potency. Xenobiotica. 16, 129 (1986).
8. D. Lessard, F. Beaudry and A. Niggebrugge, A new high sensitivity HPLC MS MS method for the determination of selegiline and desmethylselegiline in human plasma. Pharm. Res., 11(10 suppl.), S-17 (1994).
9. F. C. Lam, C. T. Hung and D. G. Perrier, Estimation of variance for harmonic mean half-lives. J. Pharm. Sci. 74, 229 (1985).
10. SAS Institute, Cary, NC.
11. Scientist, Micromath User's Handbook, Salt Lake City, UT. 1995.